CC0 PUBLIC RECORD GRAPH Every score & timeline item links directly to its underlying U.S. FDA record (openFDA, ORA FOIA Reading Room, DECRS & OASIS).
FG
GMPGraphv2.0
Global FDA Facility Graph & Co-Packer Intelligence
Form 483 Library → Wells Pharma of Houston LLC → 483-3016710931-20260413
Form FDA 483 · Issued 2026-04-13

Wells Pharma of Houston LLC — FDA Form 483 Analysis

FEI: 3016710931 · Sector: Pharmaceuticals & Sterile/OTC Drugs (Outsourcing Facility) · Lead Investigator: Elena R. Rostova

FDA Form 483 issued to Wells Pharma of Houston LLC (FEI 3016710931) on 2026-04-13 following an inspection of its outsourcing facility operations in Texas. The report documents 3 inspection observations centered on Incoming Ingredient Identity Testing & COA Qualification.

Get Full Annotated 483 Dossier + CAPA Checklist
Instant PDF + CFR Matrix ($79 vs. Redica's $289)
Buy Dossier ($79)
Need Help Fixing These 3 Citations?
Get matched with a vetted 21 CFR remediation consultant
Request Consultant

Observation-by-Observation 21 CFR Breakdown (3)

Observation #1 · 21 CFR 211.137(a) Incoming Ingredient Identity Testing & COA Qualification
FIRST-TIME OBSERVATION
Expiration date lacking
Inspector Observation Language: "Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use. Specifically, observed during inspection of Wells Pharma of Houston LLC on 2026-04-13."
Plain-English Meaning: Failure to perform at least one test to verify the identity of every incoming dietary ingredient or raw component before use, or relying on a supplier's Certificate of Analysis (COA) without first qualifying the supplier.
Standard CAPA Remediation Path: Establish SOP-QA-004 requiring FTIR/HPLC/organoleptic identity testing on 100% of incoming dietary ingredient lots and annual audit + 3-lot confirmatory testing before relying on any vendor COA.
Observation #2 · 21 CFR 211.84(d)(1) Incoming Ingredient Identity Testing & COA Qualification
REPEAT CITATION AT FACILITY
Component identity verification
Inspector Observation Language: "Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed. Specifically,observed during inspection of Wells Pharma of Houston LLC on 2026-04-13."
Plain-English Meaning: Failure to perform at least one test to verify the identity of every incoming dietary ingredient or raw component before use, or relying on a supplier's Certificate of Analysis (COA) without first qualifying the supplier.
Standard CAPA Remediation Path: Establish SOP-QA-004 requiring FTIR/HPLC/organoleptic identity testing on 100% of incoming dietary ingredient lots and annual audit + 3-lot confirmatory testing before relying on any vendor COA.
Observation #3 · 21 CFR 211.68(b) Equipment Qualification (IQ/OQ/PQ), Calibration & Water Systems
FIRST-TIME OBSERVATION
input/output verification
Inspector Observation Language: "Input to and output from [the computer] [related systems of formulas] [records or data] are not checked for accuracy. Specifically, observed during inspection of Wells Pharma of Houston LLC on 2026-04-13."
Plain-English Meaning: Scales, thermometers, pH meters, autoclaves, or purified water systems lacking current NIST-traceable calibration or process validation.
Standard CAPA Remediation Path: Tag all critical measuring instruments with calibration due dates, lock out overdue devices, and perform weekly TOC/conductivity/bioburden testing on purified water loops.